HTA Topic Prioritization – Antiviral Therapy
2024
Prioritization submission for an innovative antiviral for infectious diseases


Our clients—across pharma, global health agencies, and government—trust us because we don’t just deliver reports; we deliver results they can stand behind.
We are proud to have earned the continued confidence of multinational companies, development partners, and national health institutions, with repeat engagements and consistently high satisfaction across projects. Whether it’s guiding an HTA submission, quantifying health impact, or shaping national policy, we partner with our clients to drive outcomes that matter.

We specialize in end-to-end HTA support, helping private sector innovators succeed within the Philippine HTA system. From prioritization to dossier development and engagement with the HTA Council, we build submissions that are scientifically rigorous, locally grounded, and stakeholder-ready.
What our clients value: Clear guidance, deep understanding of HTA Philippines, and submissions that gain traction with decision-makers.



2024
Prioritization submission for an innovative antiviral for infectious diseases
2024
Strategic dossier for advanced mRNA-based vaccine
2024
Topic appeal submission for monoclonal antibody therapy
2024
Full HTA for a hematologic cancer treatment
2024
HTA for improved insulin formulation for diabetes
2024
HTA for dual-purpose metabolic therapy
2024
Expedited HTA for advanced clotting factor therapy
2024
Full HTA and topic nomination for viral prevention
2024
Full HTA for public health protection via bacterial vaccine
2024
Full HTA for vaccine against respiratory infections
From costing and economic modeling to equity analysis and global health training, our HEOR work informs policy, guides investments, and supports better health system decisions. We are proud to be a trusted partner of WHO, UNICEF, academic leaders, and regional health institutions.
What our clients value: Contextualized insights, technical rigor, and deliverables that translate directly into policy action.




2021
Policy landscape analysis for DOH & WHO
2021
National market assessment with FIND
2022
HTA + BIA of a novel biologic treatment
2022
Coverage and pricing impact analysis
2023
Cost structure design for UNICEF and DOH
2022–2025
Capacity building with Univ. of Washington
2024
COI and BOD study on obesity burden
2024
Evaluation of equity-focused HE methods in Zamboanga
